Shanghai-headquartered human-robot interaction startup Emotibot Technology Limited on Friday said it has received 200 million yuan ($30 million) in its Series C round of financing led by Bank of China’s Hong Kong-based subsidiary BOC International Holdings.
Bank of Communications arm BOCOM International Holdings Company participated as a new investor while return backer Lingfeng Capital also joined in the round.
Emotibot will use the funds towards product consolidation, commercialisation and partnership expansion.
Co-founded in 2015 by Kenny Chien, a Partner Director of Engineering at Microsoft, Emotibot is ramping up efforts to develop emotional AI robots driven by human-computer interaction and natural language technology.
Emotibot had raised $45 million in its Series B+ funding from V Fund, Puhua Capital, Lingfeng Capital, Zhong An Asset Management and others in 2019. Earlier in 2018, Emotibot had garnered $30 million in its Series B round from CDIB Venture Capital, Cathay Financial Holdings, Ecovacs and Advantech Capital in 2018.
CHINA DEAL MONITOR
DealStreetAsia has also put together a table listing out all prominent venture capital transactions in the Greater China region on November 5-6, 2020.
|Startup||Headquarter||Investment Size (USD)||Investment Stage||Lead Investor(s)||Other Investor(s)||Verticals|
|VIPThink||Beijing||180 million||C||SoftBank's Vision Fund 2||Cai Doingqing's family foundation, New Oriental, DCM, Sinovation Ventures, Enlight Grwoth Partners||EdTech|
|eSign||Hangzhou||150 million||D||Shenzhen Capital Group, Evergrande High-Tech Group, Fortune Capital||Grande Flight Investment, Fanchuang Capital, Gobi Partners China, THE Capital||N/A|
|Yuntongxun||Beijing||125 million||F||China State-Owned Capital Venture Investment Fund||Neworiental Corporation's industry fund, Mirae Asset,Parantoux Capital, CloudAlpha||Cloud Computing|
|Beijing Zhiketong Technology||Beijing||50 million||D||Vision Plus Capital||Axiom Asia, Sequoia Capital China, Shunwei Capital, Yijing Capital, CYTS Hongqi Fund||Saas|
|ZM Biopharma||Shanghai||35 million||A||Trinity Innovation Fund||SDIC Unity Capital, Oceanpine Healthcare Fund, South China Venture Capital, Photon Fund, Yueze Capital||HealthTech|
|Emotibot Technology||Shanghai||30 million||C||BOC International Holdings||BOCOM International Holdings Company, Lingfeng Capital||Robotics & Drones|
|Abogen Biosciences||Suzhou||23 million||A||SDIC Venture Capital||Hillhouse Capital, Chengdu Kanghua Biological||HealthTech|
|Runzhe Education||Leshan||15 million||Strategic Investment||Zhongdi Asset Management||-||EdTech|
|DPT||Suzhou||* 1.4 million||Angel+ round||Yunhao Capital||-||N/A|
|Shensaier||Shenzhen||-||Strategic Investment||-||Yingke Capital||N/A|
|Naruida||Zhuhai||-||Equity Financing||-||Xingwang Investment||N/A|
∗ indicates that the company did not provide the specific size of the deal but only a range. So, we adopt the smallest number in the range, which is “10 million yuan ($1.4 million)” in the given example.